Neurology/psychiatric H. Lundbeck A/S and Contera …

… discovery®, OligoDisc®, and SpliceMatrix® — alongside Lundbeck’s extensive neuroscience expertise accumulated … and Head of Research at Lundbeck. “The collaboration perfectly supports … External Research and Innovation at Lundbeck, noted that early-stage …

… the potential to significantly enhance Lundbeck’s research pipeline for … external collaborations with scientific innovators. Lundbeck vice-president and external research … (EC) approved Otsuka Pharmaceutical and Lundbeck’s atypical oral antipsychotic Rxulti …

… external collaborations with scientific innovators. Lundbeck vice-president and external research … to alter disease progression. Lundbeck holds the option for global … (EC) approved Otsuka Pharmaceutical and Lundbeck’s atypical oral antipsychotic Rxulti …

… candidates against targets provided by Lundbeck. Through the collaboration, neurology specialist … Lundbeck retains the option to advance … disclosed, a comparison with similar Lundbeck deals suggests that around US …

… , Inovio, Insmed, Ipsen, Karuna, Lilly, Lundbeck, Mirati, Moderna, Novartis, Novavax, Novo …

… Inc. Novartis AG Lundbeck A/S H. Lundbeck A/S …

… Inc., Pfizer Inc., Novartis AG, Lundbeck A/S Regional Highlights … , Teva, AbbVie, Pfizer, Novartis, and Lundbeck are investing heavily in next …

… from Boehringer Ingelheim, Recordati, Lundbeck, Otsuka, Janssen, CNX Therapeutics … Medical Education, Invicro, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Rand … Boehringer Ingelheim, Eli Lilly, LivaNova, Lundbeck, Sunovion, Servier, Janssen, Allergan …

… well as updates from Roche, Lundbeck and Viridian Therapeutics that you … to $2 billion. — Jonathan Gardner Lundbeck and Contera Pharma have entered … research for each novel target. Lundbeck also retains the option to …